Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.
A three-drug combination achieved complete remission in nearly all treatment-resistant acute leukemia patients, with half remaining in long-term remission after a median of three years.
Gilteritinib + azacitidine + venetoclax triplet in FLT3+ R/R AML: ORR 100%, composite CR (mCRc) 93%; 62% bridged to allo-HSCT; 50% of transplanted patients in long-term remission at median 43-month follow-up. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- retrospective_cohort
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- British Journal of Haematology
Why it surfaced
Compelling real-world efficacy for FLT3+ R/R AML triplet salvage; landmark ORR 100% with durable remissions in very high-unmet-need disease; published in Br J Haematol.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.